Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
SMALL CAP BASIC
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type | ISIN | Company Description |
|---|---|---|---|---|---|
| Merck & Company (New) | MRK | NYSE | Ordinary Share | US58933Y1055 |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| +0 | +0% | 65.6 | - | - | - | 65.6 | 09:20:15 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | - | - | USD |
| Industry Sector |
|---|
| Drug Manufacturers - Major |
Merck & Company (New) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| US$ 178.91B | 2.73B | US$ 3.92B | 1.42 | 46.60 | 2.74B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | US$ 1.88 | 2.87% | 09/14/2017 | - | 71.60% |
Merck & Company (New) News
Pro Baseball Hall of Famer & Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly & Leading Cancer Organizations To Expand You... Business Wire • Tue Sep 19, 2017 7:00 AM (3 days ago)
ISENTRESS® HD (raltégravir), un antirétroviral nouvellement en prise quotidienne unique en association avec d'autres antir... PR Newswire (Canada) • Tue Sep 12, 2017 2:20 PM (1 week ago)
Now Available in Canada: ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agen... PR Newswire (Canada) • Tue Sep 12, 2017 2:20 PM (1 week ago)
Merck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Pre... Business Wire • Mon Sep 11, 2017 9:00 AM (2 weeks ago)
Merck’s KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follo... Business Wire • Sun Sep 10, 2017 8:45 AM (2 weeks ago)
Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembro... Business Wire • Sat Sep 09, 2017 8:45 AM (2 weeks ago)
Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed & Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Resp... Business Wire • Fri Sep 08, 2017 10:33 AM (2 weeks ago)
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRK Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 66.17 | 66.41 | 65.19 | 65.9295 | 5M | 11M | 7M | -0.57 | -0.86% |
| 1 Month | 62.87 | 66.41 | 62.72 | 64.7106 | 5M | 13M | 7M | 2.73 | 4.34% |
| 3 Months | 64.49 | 66.41 | 61.16 | 63.5370 | 4M | 22M | 7M | 1.11 | 1.72% |
| 6 Months | 63.4 | 66.41 | 61.16 | 63.6423 | 3M | 22M | 8M | 2.2 | 3.47% |
| 1 Year | 62.87 | 66.8 | 58.29 | 62.9283 | 2M | 33M | 9M | 2.73 | 4.34% |
| 3 Years | 59.72 | 66.8 | 45.69 | 58.4321 | 0 | 69M | 9M | 5.88 | 9.85% |
| 5 Years | 45.05 | 66.8 | 40.02 | 53.9770 | 0 | 69M | 11M | 20.55 | 45.62% |
